Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.

Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to ...

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 ...

Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license ...

R. Jude Samulski, Ph.D., was honored by the American Society of Gene + Cell Therapy (ASGCT) with its Founders Award at the ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated ...

A young nurse and mother initially thought the red spot on her tongue was the physical toll of a bad breakup, but the reality ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

The resignation comes after reports suggested the President was considering firing him.

Roche said its $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch ...